bpc-157 clinical trials humans safety This is the first vote from the FDA's Pharmacy Compounding Advisory Committee on one of 7 peptides up for consideration. While the committee advises through these votes, ultimately the FDA will make bpc-157 human clinical trials evidence

Tendon Fibroblast and Growth-Factor Research Findings published by Chang and others investigated BPC-157 in tendon fibroblasts (also called tenocytes responsible for creating and repairing tendons)

[DOI] [PubMed] [Google Scholar] 28.Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK: Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men

In preclinical studies this reduced fat-cell size without changes to diet

In animal models, intranasal administration of GHK-Cu improved cognitive functions, reduced amyloid plaques, and decreased inflammation in the brain, suggesting its potential as a therapeutic agent for Alzheimers disease and age-related cognitive decline 10

The exact schedule is set by the clinical team for each patient rather than copied from a template, and any dosing decisions are made in the visit, not from a webpage